A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 microg by Intracerebroventricular Infusion

Trial Profile

A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 microg by Intracerebroventricular Infusion

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs SNN 0031 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Newron Sweden AB
  • Most Recent Events

    • 26 Jan 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jul 2014 Planned End Date changed from 1 Oct 2014 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top